

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURES AND OTHER INTERNAL POLICIES

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) pursuant to Rule 13.51 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Please also refer to the overseas regulatory announcement of the Company dated 29 April 2024.

In light of updates in applicable laws and regulations, including the Company Law of the People's Republic of China* (《中華人民共和國公司法》), the Guidelines for Articles of Association of Listed Companies (2023 Revision)* (《上市公司章程指引(2023年修訂)》), Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies* (《境內企業境外發行證券和上市管理試行辦法》) and the Measures for the Administration of Independent Directors of Listed Companies (《上市公司獨立董事管理辦法》), the board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes to amend (i) the articles of association of the Company (the “**Articles of Association**”), (ii) the rules of procedures of the meetings of the Board (the “**Rules of Procedures of the Board of Directors**”), (iii) the rules of procedures of the meetings of the board of supervisors of the Company (the “**Rules of Procedures of the Board of Supervisors**”), and (iv) the rules of procedures of general meeting (the “**Rules of Procedures of General Meeting**”), together with the Rules of Procedures of the Board of Directors, the Rules of Procedures of the Board of Supervisors, the “**Rules of Procedures**”).

Other internal policies that the Company proposes to amend include the (i) working rules of independent non-executive Directors, (ii) terms of reference of the nomination committee of the Board, (iii) terms of reference of the strategic committee of the Board, (iv) terms of reference of the remuneration and assessment committee of the Board, (v) terms of reference of the audit committee of the Board, (vi) working rules of general manager, (vii) working rules of the Board secretary, (viii) information disclosure management policies, (ix) information disclosure suspension and exemption business management policies, (x) investor relations management policies, (xi) internal audit management policies, and (xii) management policies in relation to the prevention of controlling shareholders and related parties from appropriating funds of the Company, (xiii) administrative policies for external guarantees, (xiv) administrative policies for external investment, (xv) management policies for related party transactions, (xvi) management policies for distribution of profits, and (xvii) management policies for raised funds. Save for the the working rules of independent non-executive Directors, administrative policies for external guarantees,

administrative policies for external investment, management policies for related party transactions, management policies for distribution of profits and management policies for raised funds, the proposed amendments to the aforesaid internal policies have been reviewed and approved by the Board.

The proposed amendments to the Articles of Association, the Rules of Procedures, the working rules of independent non-executive Directors, administrative policies for external guarantees, administrative policies for external investment, management policies for related party transactions, management policies for distribution of profits and management policies for raised funds shall be subject to the shareholders' approval by way of ordinary resolution or special resolution at a general meeting and class meetings to be convened by the Company. A circular containing, among other things, details of the aforesaid proposed amendments will be issued to the shareholders of the Company as soon as practicable.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 29 April 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Feng Hui and Mr. Tang Yi as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*